Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase NA 2Phase 4 1Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 277Pain, Postoperative 14Neoplasm Metastasis 12Neoplasms 9Prostatic Neoplasms 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 6Pain 6Osteoporosis 6Seroma 5Colorectal Neoplasms 5Cardiotoxicity 5Breast Diseases 4Breast Cancer Female 4Neutropenia 3Melanoma 3Mastodynia 3Lymphedema 3Lung Neoplasms 3Head and Neck Neoplasms 3Brain Neoplasms 3Bone Diseases, Metabolic 3Vomiting 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sleep Initiation and Maintenance Disorders 2Skin Diseases 2Obesity 2Neurotoxicity Syndromes 2Multiple Myeloma 2

Interventions

Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Primary Breast Cancer × Breast × Clear all
NCT03270007 2020-10-28

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Peking University

Phase 4 Unknown
304 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡